42 results about "Doxorubicinone" patented technology

The present application relates to providing a doxorubicin-loaded anti-tumor hemostatic microsphere constructed by a simple, safe and low-cost method and its preparation and application, the doxorubicin-loaded anti-tumor hemostatic microsphere comprises alginate, hemostatic component A, doxorubicin or doxorubicin liposome, crosslinking agent, the hemostatic component A is selected from one or more of carboxymethyl chitosan, hyaluronic acid, collagen, silk fibroin, solve the practical pain point problems such as easy bleeding in tumor resection surgery, large toxicity of chemotherapeutic drugs, large drug dose, frequent drug administration, etc., realize rapid hemostasis in operation, postoperative precise targeted drug delivery, reduce toxic side effects, long-acting drug sustained release, at the same time, all components of the system are safe and reliable, and have good biocompatibility.

The invention relates to the technical field of nano materials, in particular to a preparation method of a Zn-based bimetal MOFs material and application of the Zn-based bimetal MOFs material as a medical drug carrying material. The preparation method comprises the following steps: preparing Zn, Mn and a ligand according to a molar ratio of 1: 1: (72-80), and mainly comprises the steps of preparation of metal salt solutions, coordination polymerization reaction, separation and purification, and drying. The process for preparing the Zn-based bimetallic MOFs material is simple and environmentally friendly, the obtained product has the excellent performance of being small in particle size, regular and stable, and the material loaded with doxorubicin hydrochloride has high loading rate and has potential clinical conversion value.

The present invention discloses a colorectal cancer radiotherapy sensitizing drug and its application, belonging to the field of biomedicine, and specifically relates to a colorectal cancer radiotherapy sensitizing drug, comprising a pharmaceutical active ingredient and a solvent, wherein the pharmaceutical active ingredient comprises doxorubicin and a nitrogen-containing compound, wherein the nitrogen-containing compound comprises quinoline-6-carbohydrazide and N-benzyloxymethyl-4-nitroimidazole. The colorectal cancer radiotherapy sensitizing drug disclosed in the present invention focuses on FOXP4, a key driver gene of colorectal cancer radiotherapy resistance, and degrades FOXP4 protein through the ubiquitin-proteasome pathway. This not only significantly increases the sensitivity of tumor cells to radiotherapy, inhibits tumor growth, and reduces damage to normal tissues; it also effectively circumvents the drug resistance problem that is prone to occur with traditional methods, significantly reduces R&D costs, accelerates clinical transformation, and has good clinical application prospects.

This invention belongs to the field of biomedical technology, specifically disclosing a nanomicelle FluDox-MIC, its preparation method, and its uses. This nanomicelle is formed by the self-assembly of flumatinib and doxorubicin co-loaded in mPEG-DSPE, exhibiting pH-responsive release properties. Upon entering the tumor microenvironment, it releases the drug. The released flumatinib induces the degradation of the poliovirus receptor (PVR / CD155), relieving its inhibitory signal on NK cells and reactivating innate immune surveillance. Simultaneously, low-dose doxorubicin induces significant immunogenic cell death (ICD), initiating and amplifying tumor-specific T cell-mediated adaptive immunity. Through the synergistic activation of innate and adaptive immunity, the nanomicelle of this invention can effectively inhibit melanoma growth and overcome immunotherapy resistance, showing promising clinical application prospects.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

Provided is a use of a compound represented by general formula (I) in combination with doxorubicin in the preparation of an anti-cancer drug

A pharmaceutical composition for preventing and / or treating tumors, which pharmaceutical composition contains the following topoisomerase II inhibitors as active ingredients: doxorubicin, etoposide, idarubicin, amsacrine, aclarubicin, teniposide, epirubicin, and pirarubicin. The pharmaceutical composition, compared with any one of the components therein, has significantly enhanced tumor inhibitory effects and significantly reduced toxic side effects, wherein a synergistic effect is present among the components.

The application belongs to the technical field of high-molecular anti-tumor drug delivery carriers, and particularly relates to an oxygen-deficient bioreduction responsive amphiphilic block polymer anti-tumor drug carrier and a preparation method and application thereof. The oxygen-deficient responsive block copolymer (POC7A-PCL) with a hydrophobic segment of PCL and a hydrophilic segment of POC7A is constructed through ring-opening polymerization and atom transfer radical polymerization. The polymer is used to load an anti-tumor drug doxorubicin to construct a responsive polymer nanoparticle, which shows stronger anti-tumor capacity. Therefore, the POC7A-PCL can be applied to the preparation of anti-tumor drugs as a drug carrier.

The invention discloses a pharmaceutical composition containing a polysialic acid-melittin polyion compound and sialic acid modified anthracycline anti-tumor drug liposome and application of the pharmaceutical composition. The invention belongs to the technical field of biological medicine, and particularly relates to a targeted delivery pharmaceutical composition for treating cold tumors through immunotherapy, and the pharmaceutical composition comprises a polysialic acid-melittin polyion compound and sialic acid modified anthracycline antitumor drug liposome. The anthracycline antitumor drug is selected from one or more of the following components: doxorubicin, epirubicin, pirarubicin, idarubicin, daunorubicin or mitoxantrone. The pharmaceutical composition shows a remarkable synergistic effect in tumor inhibition index, can stimulate congenital immunity and adaptive immunity, induce multiple release of tumor-associated antigens and specific antigens, trigger tumor immune circulation and recover immune control of a body on tumors, and also can enable the body to generate immune memory, so that the tumor inhibition effect is improved. And a new combined treatment strategy is provided for cold tumor treatment.

The invention belongs to the technical field of biomedical materials and tumor treatment, and discloses a biological orthogonal catalytic microneedle based on a cytotoxic polyethyleneimine matrix as well as a preparation method and application of the biological orthogonal catalytic microneedle. The microneedle patch comprises a backing layer and a microneedle array, wherein the microneedle array is formed by mixing polyvinyl alcohol (PVA) loaded with metal nanoparticles and polyethyleneimine (PEI) with a hydrogel matrix. According to the invention, the inherent cytotoxicity (membrane destroying ability) of PEI is creatively combined with the catalytic activity of a metal catalyst (such as palladium) to construct a synergistic treatment system which turns toxins into treasures. The PEI matrix has dual functions in the microneedle: on one hand, the PEI matrix is used as a potent ligand to anchor and stabilize the metal nanoparticles and prevent the metal nanoparticles from leaking; on the other hand, as a therapeutic agent, tumor cell membranes are destroyed through electrostatic interaction. The microneedle patch is activated by catalyzing a prodrug (such as doxorubicin protected by propargyloxycarbonyl) in situ, meanwhile, the physical membrane destruction effect of PEI is utilized, the synergistic anti-tumor effect of physical destruction and chemical killing is achieved, and the treatment efficiency of superficial tumors such as melanoma is remarkably improved.

The invention relates to the technical field of pharmaceutical preparations, and discloses a doxorubicin and cyclophosphamide liposome compound injection which is prepared from doxorubicin hydrochloride, cyclophosphamide, hydrogenated soybean phosphatidylcholine, cholesterol, polyethylene glycol derivative phospholipid, anhydrous magnesium sulfate, L-arginine and a sucrose octasulfate ammonium solution. Magnesium ions introduced into an inner water phase participate in competitive binding, doxorubicin and sucrose octasulfate are induced to form a loose co-precipitation structure with lattice defects, hydrophilic cyclophosphamide is physically filled and cured by using micro gaps, and efficient encapsulation of non-gradient dependent drugs is realized. Meanwhile, an in-situ pH buffer system is constructed by using L-arginine, protons generated in a drug loading process are neutralized, an internal water phase is maintained in a neutral environment, and acid-catalyzed hydrolysis of cyclophosphamide is effectively inhibited. According to the invention, the double-drug encapsulation efficiency and storage stability of the compound liposome are obviously improved.

The present invention relates to the field of cancer therapies. In particular, the present invention relates to the development of new therapies for the treatment of solid tumours. The present invention relates to a combination of a peptide derived from the venom of the spider species Phoneutria nigriventer, especially the LW-9 fraction, and classic chemotherapeutic agents, in particular doxorubicin, as an alternative for the treatment of solid tumours, including breast cancer. Additionally, the present invention describes a kit comprising an effective dosage form of peptide fractions of the venom of the spider species Phoneutria nigriventer, an effective dosage form of an anthracycline, and instructions for use. An additional objective of the present invention is to describe a composition comprising the peptide fraction LW-9 as well as the use thereof in the treatment of solid tumours.

The application discloses a compound capable of targeted degradation of MYC and application thereof, and belongs to the technical field of medicines. The compound can target degradation of MYC after entering a patient's body, thereby effectively inhibiting the proliferation of tumor cells such as lymphoma and osteosarcoma and cancer cells such as colorectal cancer, and having good anti-tumor effect and anticancer effect; the compound can also inhibit the proliferation of myelomonocytic leukemia cells in the patient's body, thereby providing a new treatment scheme for treating myelomonocytic leukemia; the compound has a synergistic effect when combined with doxorubicin, has better anti-tumor activity, and has a wide application prospect in the field of medicines.

The invention belongs to the technical field of biological medicines, and discloses a new medical application of an hERG / Kv11.1 channel activator NS-1643, so that new application of old medicines is realized. The NS-1643 is traditionally used for anti-arrhythmia research and development, it is found for the first time that NS-1643 can effectively treat cardiotoxicity induced by anthracycline drugs (such as doxorubicin), and meanwhile NS-1643 can be used for preventing or treating ferroptosis-related cardiovascular diseases such as myocardial ischemia reperfusion injury, myocardial infarction and heart failure. The invention further provides a pharmaceutical composition containing the NS-1643, the NS-1643 or pharmaceutical salt, ester, solvate and the like of the NS-1643 are taken as active ingredients of the composition, and the active ingredients are matched with auxiliary ingredients acceptable in biological pharmacy, so that the composition can be prepared into sterile dosage forms such as injections, oral preparations and the like, and the process is stable and controllable. Cell experiments prove that NS-1643 has a remarkable protective effect on ferroptosis-induced myocardial cell injury (EC50 is approximately equal to 2.7 mu M); animal experiments prove that the doxorubicin-induced mouse death risk can be completely reversed, the heart function is remarkably improved, and myocardial fibrosis and lipid peroxidation damage are relieved. The application expands the clinical application range of NS-1643, has the advantages of high clinical transformation potential, clear treatment effect and the like, provides a new effective strategy for prevention and treatment of anthracycline cardiotoxicity and related cardiovascular diseases, and has important clinical application value and industrial transformation prospect.

The application discloses a nanoscale coordination polymer NP@DoxCu based on copper ions and doxorubicin as well as a preparation method and application thereof, and relates to the technical field of ovarian cancer treatment. 2+ The nanoscale coordination polymer NP@DoxCu uses a ROS-sensitive polymer PSSP, doxorubicin Dox and Cu 2+ The application constructs a ROS-sensitive copper apoptosis nanoplatform NP@DoxCu. 2+ The platform is rapidly decomposed under the action of intracellular reductase and in a low-pH environment after entering cells; Cu 2+ cooperates with doxorubicin to not only directly kill cancer cells but also induce immune cell death; in addition, the NP@DoxCu remodels the tumor immune microenvironment, reorients tumor-associated macrophages (TAMs) and regulates T cells, thereby realizing effective immunotherapy in vivo; the combination of the copper apoptosis and the immunotherapy provides a new strategy for the treatment of ovarian cancer.

The invention discloses an Au-coated Ag / C-CNF / PEGDA hydrogel SERS (Surface Enhanced Raman Scattering) sensor as well as a preparation method and application thereof, and belongs to the technical field of analysis and detection. Gold and silver nanoparticles with a core-shell structure, polyethylene glycol diacrylate and carboxylated cellulose react to form an Au-coated Ag / C-CNF / PEGDA hydrogel prepolymer solution, and the hydrogel prepolymer solution is subjected to ultraviolet crosslinking under the action of a photoinitiator to form the porous three-dimensional network structure Au-coated Ag / C-CNF / PEGDA hydrogel SERS sensor with a synergistic effect. The hydrogel sensor provided by the invention not only can accurately detect 10 <-9 > M-10 <-5 > M Raman signal molecule rhodamine 6G (R6G), but also has good sensitivity and excellent uniformity, the RSD is as low as 4.92%, and the detection limits on anthracycline antitumor drugs doxorubicin (DOX) and mitoxantrone (MTO) respectively reach 3.4 * 10 <-8 > M and 3.6 * 10 <-9 > M.

The invention relates to a pharmaceutical composition for preventing and / or treating tumors. The pharmaceutical composition comprises the following topoisomerase II inhibitors as active ingredients: doxorubicin, etoposide, idarubicin, anacridine, acarubicin, teniposide, epirubicin and pirarubicin. Compared with any one of the components, the pharmaceutical composition disclosed by the invention has a remarkable tumor inhibition effect, the toxic and side effects are obviously reduced, and all the components have a synergistic effect.

This invention belongs to the field of liposome formulation and preparation technology, specifically relating to a doxorubicin hydrochloride liposome and its preparation method. A specific concentration of ammonium sulfate aqueous solution and an oil phase solution containing lipid components are prepared. Microfluidic technology is used to mix the oil phase and aqueous phase at a flow rate ratio of 1:3 to 1:5 to form blank liposomes. A first hydration and a second hydration with the addition of ammonium sulfate aqueous solution are performed sequentially to achieve a final oil-water ratio of 1:6 to 1:10. After ultrafiltration to remove impurities from the external aqueous phase, doxorubicin hydrochloride solution is added to complete drug loading. This method, by optimizing microfluidic mixing parameters and a two-step hydration process, successfully prepares liposomes with uniform particle size distribution, stable internal ammonium sulfate concentration, and excellent in vitro release. Furthermore, the ultrafiltration process is bubble-free, significantly improving formulation stability, controllable drug release, and batch consistency, providing a reliable solution for the industrial production of high-quality doxorubicin hydrochloride liposomes.

This invention discloses a helical elongated cavity multi-walled mesoporous silica microparticle, its preparation method, and its application, relating to the field of materials preparation technology. The technical solution involves dissolving dimethylbis(tetradecyl)ammonium bromide in water, adding an alkaline solution, stirring thoroughly to obtain a mixed solution, then adding a silicate ester and stirring to react; the product is purified by centrifugation, washed with water, and ultrasonically treated in an acidic ethanol solution to obtain helical elongated cavity multi-walled mesoporous silica microparticles. The elongated cavities of this invention extend helically in the same plane, and the cavity walls have a concentric tubular multilayer structure, thus possessing a "multi-walled" structure; using doxorubicin as a model small molecule drug, these microparticles exhibit efficient loading and sustained-release capabilities.

The application relates to application of TNFRSF13B in preparation of a medicine for treating relapsed refractory diffuse large B-cell lymphoma. Research finds that TNFRSF13B has specific expression in relapsed refractory diffuse large B-cell lymphoma and is closely related to the survival of DLBCL patients, in-vitro cell experiments and in-vivo animal experiments verify that TNFRSF13B plays an important role in maintaining the clonal formation ability, continuous passage proliferation and doxorubicin resistance phenotype, and the blocking can significantly inhibit the tumor initiation ability, which indicates potential application value of TNFRSF13B in diagnosis, prognosis evaluation and treatment of relapsed refractory diffuse large B-cell lymphoma.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating doxorubicin cardiomyopathy, and belongs to the technical field of traditional Chinese medicine compositions. The technical problems to be solved are that the curative effect is limited, the toxic and side effects are great, and the preventive intervention on doxorubicin cardiomyopathy is insufficient. The invention provides a traditional Chinese medicine composition for treating doxorubicin cardiomyopathy. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6 parts of American ginseng, 9 parts of ginseng slices, 20 parts of astragalus membranaceus, 15 parts of raw spina date seeds, 15 parts of salvia miltiorrhiza, 9 parts of pseudo-ginseng slices, 10 parts of prepared fingered citron and 10 parts of ginger processed mangnolia officinalis. The traditional Chinese medicine composition can be used for treating or preventing doxorubicin cardiomyopathy, improving the heart function of doxorubicin cardiomyopathy mice, eliminating myocarditis, promoting repair and regeneration of myocardial cells, improving myocardial remodeling and improving the contraction function of the heart.

The present invention relates to the field of tumor treatment technology, and specifically discloses the use of an HVEM inhibitor in the preparation of a drug for treating acute lymphoblastic leukemia. The present invention utilizes CRISPR / Cas9 gene editing technology to knock out the HVEM gene on tumor cells, thereby enhancing the body's anti-tumor immune response and significantly inhibiting tumor growth. Mechanistically, the present invention demonstrates that the anti-tumor immune response mediated by HVEM deficiency depends on CD8 + T cells, and HVEM, through its CRD1 domain, enables tumor cells to escape the body's immune surveillance, thereby promoting tumor progression. Furthermore, by knocking out the HVEM gene on tumor cells and combining it with doxorubicin chemotherapy, mice inoculated with acute lymphoblastic leukemia can achieve disease-free survival and induce immune memory in the body, effectively preventing tumor recurrence. This provides a new drug target for immunotherapy combined with chemotherapy for acute lymphoblastic leukemia.

The invention relates to the technical field of medicine, and discloses an application of doxorubicin liposome and albumin paclitaxel in preparation of tumor treatment drugs, a combined medication scheme of the doxorubicin liposome and albumin paclitaxel is not recorded by any colorectal cancer related diagnosis and treatment guideline at present, and the doxorubicin liposome and albumin paclitaxel liposome is an over-indication medication scheme.

The invention belongs to the technical field of material science and biological medicine, and particularly relates to a drug-loaded magnetic porous alumina composite material as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing magnetic nanoparticles with doxorubicin to obtain a suspension; and immersing the nano-porous anodic aluminum oxide in the suspension, drying, coating the surface with a chitosan solution, and drying to obtain the drug-loaded magnetic porous aluminum oxide composite material. The drug-loaded magnetic porous alumina composite material has magnetic response capability and controllable gating performance, so that the drug release mode is changed from traditional passive diffusion to external controllable on-demand release, and the time, space and dosage accuracy of the release process is remarkably improved.

The present invention relates to co-therapies comprising a metastasis inhibitor. The present invention provides the use of a compound having the following structure, or a tautomer thereof, and / or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for increasing the response to a chemotherapeutic agent in a patient in need thereof: # imgabs0 # wherein the patient is or is about to undergo chemotherapy; and wherein the chemotherapeutic agent is paclitaxel, cyclophosphamide, or doxorubicin. The invention also provides the use of the above-mentioned substances in the preparation of a medicament for treating cancer in a patient in need thereof and for administration in combination with a chemotherapeutic agent, the use of the above-mentioned substances in the preparation of a medicament for increasing the response to an immunotherapeutic agent in a patient in need thereof, and the use of the above-mentioned substances in the manufacture of a medicament for the treatment of cancer in a patient in need thereof and for administration in combination with an immunotherapeutic agent.

Disclosed are methods and compositions for repolarizing a macrophage from M2 to M1 comprising administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more CD206 targeting moieties conjugated thereto. In certain aspects, the compound further comprises a therapeutic agent selected from: paclitaxel, gemcitabine, lapatinib, and doxorubicin. In further aspect, the therapeutic agent comprises a chelator and at least one metal ion. In certain implementations, the at least one metal ion comprises at least one Cu(II) ions.

The invention relates to the technical field of medicines for treating hand-foot syndrome and breast cancer, in particular to a composition for preventing and / or treating hand-foot syndrome (HFS) and synergistically resisting breast cancer as well as a preparation method and application of the composition. The composition comprises CuB-DOX (at) Lip, the CuB is cucurbitacine B, the DOX is doxorubicin, and the Lip is liposome. The mass ratio of CuB to DOX is 1: 5. The preparation method comprises the following steps: 1, preparing CuB-loaded lipidosome by using a film dispersion method; and 2, preparing the liposome CuB-DOX-coated Lip co-loaded with the two drugs by using an ammonium sulfate gradient method. In-vitro experiments prove that the combined application of the two medicines has the effect of treating the breast cancer. In-vivo experiments show that the compound has an obvious targeting effect. Meanwhile, the tumor growth inhibition effect of the CuB-DOX-coated Lip is obviously higher than that of a free drug group and a DOX-coated Lip group. Compared with a DOX-coated Lip group, IL-6 in a mouse in the CuB-DOX-coated Lip group is remarkably reduced, and IL-10 in the mouse in the CuB-DOX-coated Lip group is remarkably increased, which indicates that the CuB-DOX-coated Lip effectively inhibits inflammatory response in the mouse, so that the effect of preventing HFS is achieved.

The invention discloses an application of combination of KN93 and doxorubicin in prevention and treatment of tumors and tumor metastasis induced by an environmental pollutant PM2.5. Experiments find that KN93 and doxorubicin are combined as active components for use, growth and proliferation of tumors induced by an environmental pollutant PM2.5 can be remarkably inhibited, the number of pulmonary metastasis nodules is remarkably reduced compared with that of a single drug group, and good synergistic anti-tumor and anti-metastasis effects are shown. Therefore, the KN93 and the doxorubicin can be combined to be used for developing the medicine for preventing or treating the PM2.5-induced tumor and tumor metastasis.

The invention belongs to the technical field of liposome preparations and preparation thereof, and particularly relates to a doxorubicin hydrochloride liposome and a preparation method thereof. Preparing an ammonium sulfate aqueous solution with a specific concentration and an oil phase solution containing a lipid component; mixing an oil phase and a water phase according to a flow velocity ratio of 1: 3 to 1: 5 by adopting a microfluidic technology to form a blank liposome; sequentially carrying out primary hydration and secondary hydration of supplementing the ammonium sulfate aqueous solution, so that the final oil-water ratio reaches 1: 6 to 1: 10; and carrying out ultrafiltration to remove external water phase impurities, and adding a doxorubicin hydrochloride solution to finish drug loading. According to the method, by optimizing micro-fluidic mixing parameters and a two-step hydration process, the liposome which is uniform in particle size distribution, stable in internal water phase ammonium sulfate concentration and excellent in-vitro release degree is successfully prepared, no bubble exists in the ultrafiltration process, the preparation stability, the medicine controllable release property and the batch consistency are remarkably improved, and the application prospect is wide. And a reliable scheme is provided for industrial production of high-quality doxorubicin hydrochloride liposome.

This invention discloses the application of phenethyl caffeate or pterostilbene in the preparation of adjuvant drugs for the treatment of drug-resistant tumors. The study found that phenethyl caffeate can significantly improve the efficacy of doxorubicin and docetaxel against drug-resistant breast cancer and non-small cell lung cancer cells, while pterostilbene can significantly improve the efficacy of doxorubicin against drug-resistant breast cancer. This invention provides a novel treatment method combining phenethyl caffeate or pterostilbene with clinical antitumor drugs, which can significantly improve the treatment effect against drug-resistant tumors. Because phenethyl caffeate and pterostilbene are abundant, safe, and low in cost, this combination is simple and convenient to administer, making it suitable for large-scale application.